[ADPKD treatment: Tolvaptan and Octreotide].

G Ital Nefrol

UOC Nefrologia, Dialisi e Litotrissia, Ospedale Sandro Pertini Roma.

Published: December 2019

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most frequent monogenic hereditary disease as well as the most studied inherited kidney disease. Two drugs have recently been authorized that can slow down the progression of the disease: Tolvaptan (vasopressin receptor antagonist) and Octreotide-LAR (long-acting somatostatin analogue); they both are able to reduce the activity of cyclic adenosine monophosphate (cAMP) and therefore have anti-proliferative and anti-secretory effects. This review analyzes the main trials published to date demonstrating the effects on disease progression in patients with ADPKD and illustrates the indications for identifying subjects eligible for therapy.

Download full-text PDF

Source

Publication Analysis

Top Keywords

kidney disease
8
disease
5
[adpkd treatment
4
treatment tolvaptan
4
tolvaptan octreotide]
4
octreotide] autosomal
4
autosomal dominant
4
dominant polycystic
4
polycystic kidney
4
disease adpkd
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!